Hypoxic Radiosensitization: Adored and Ignored
Top Cited Papers
- 10 September 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (26), 4066-4074
- https://doi.org/10.1200/jco.2007.12.7878
Abstract
Since observations from the beginning of the last century, it has become well established that solid tumors may contain oxygen-deficient hypoxic areas and that cells in such areas may cause tumors to become radioresistant. Identifying hypoxic cells in human tumors has improved by the help of new imaging and physiologic techniques, and a substantial amount of data indicates the presence of hypoxia in many types of human tumors, although with a considerable heterogeneity among individual tumors. Controlled clinical trials during the last 40 years have indicated that this source of radiation resistance can be eliminated or modified by normobaric or hyperbaric oxygen or by the use of nitroimidazoles as hypoxic radiation sensitizers. More recently, attention has been given to hypoxic cytotoxins, a group of drugs that selectively or preferably destroys cells in a hypoxic environment. An updated systematic review identified 10,108 patients in 86 randomized trials designed to modify tumor hypoxia in patients treated with curative attempted primary radiation therapy alone. Overall modification of tumor hypoxia significantly improved the effect of radiotherapy, with an odds ratio of 0.77 (95% CI, 0.71 to 0.86) for the outcome of locoregional control and with an associated significant overall survival benefit (odds ratio = 0.87; 95% CI, 0.80 to 0.95). No significant influence was found on the incidence of distant metastases or on the risk of radiation-related complications. Ample data exist to support a high level of evidence for the benefit of hypoxic modification. However, hypoxic modification still has no impact on general clinical practice.Keywords
This publication has 55 references indexed in Scilit:
- Advanced imaging applied to radiotherapy planning in head and neck cancer: a clinical reviewThe British Journal of Radiology, 2006
- Lysyl oxidase is essential for hypoxia-induced metastasisNature, 2006
- Endogenous Markers of Two Separate Hypoxia Response Pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) Are Associated With Radiotherapy Failure in Head and Neck Cancer Patients Recruited in the CHART Randomized TrialJournal of Clinical Oncology, 2006
- Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: a meta-analysisThe British Journal of Radiology, 2005
- Clinical studies of hypoxia modification in radiotherapySeminars in Radiation Oncology, 2004
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Individual Patient- versus Literature-Based Meta-analysis of Survival Data: Time to Event and Event Rate at a Particular Time Can Make a Difference, an Example Based on Head and Neck CancerControlled Clinical Trials, 2001
- Clinical Experience with Intravenous Misonidazole for Carcinoma of the Esophagus: Results in Attempting Radiosensitization of Each Fraction of ExposureCancer Investigation, 1984
- Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervixThe British Journal of Radiology, 1978
- Radiation plus Metronidazole for GlioblastomaThe New England Journal of Medicine, 1977